$0.36
1.36%
Downside
Day's Volatility :11.23%
Upside
10.0%
1.89%
Downside
52 Weeks Volatility :95.99%
Upside
95.91%
Period | Biodexa Pharmaceuticals Plc | Index (Russel 2000) |
---|---|---|
3 Months | -61.39% | 0.0% |
6 Months | -72.32% | 0.0% |
1 Year | -94.38% | 0.0% |
3 Years | -99.04% | -22.3% |
Market Capitalization | 5.8M |
Book Value | $1.57 |
Earnings Per Share (EPS) | -10.49 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2843.37% |
Return On Assets TTM | -51.38% |
Return On Equity TTM | -180.59% |
Revenue TTM | 381.0K |
Revenue Per Share TTM | 0.48 |
Quarterly Revenue Growth YOY | -64.1% |
Gross Profit TTM | -4.4M |
EBITDA | -6.5M |
Diluted Eps TTM | -10.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 2122.22%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.9M | ↑ 95.96% |
Net Income | -10.4M | ↓ 11.42% |
Net Profit Margin | -534.98% | ↑ 648.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 882.5K | ↓ 65.22% |
Net Income | -12.0M | ↓ 11.86% |
Net Profit Margin | -1.4K% | ↓ 820.81% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 460.7K | ↓ 49.11% |
Net Income | -29.8M | ↑ 142.82% |
Net Profit Margin | -6.5K% | ↓ 5113.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 769.0K | ↑ 68.51% |
Net Income | -7.3M | ↓ 75.39% |
Net Profit Margin | -944.64% | ↑ 5524.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 850.9K | ↑ 20.93% |
Net Income | -9.3M | ↑ 40.22% |
Net Profit Margin | -1.1K% | ↓ 150.64% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 482.3K | ↓ 45.49% |
Net Income | -9.0M | ↓ 7.54% |
Net Profit Margin | -1.9K% | ↓ 762.73% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 131.0K | ↓ 50.64% |
Net Income | -2.6M | ↑ 50.11% |
Net Profit Margin | -2.0K% | ↓ 1335.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 140.6K | ↑ 0.0% |
Net Income | -2.8M | ↑ 0.0% |
Net Profit Margin | -2.0K% | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 180.8K | ↑ 29.0% |
Net Income | -2.2M | ↓ 22.35% |
Net Profit Margin | -1.2K% | ↑ 791.86% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 188.2K | ↑ 0.0% |
Net Income | -2.3M | ↑ 0.0% |
Net Profit Margin | -1.2K% | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.5K | ↓ 72.15% |
Net Income | -1.8M | ↓ 1.6% |
Net Profit Margin | -4.2K% | ↓ 3032.8% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.5K | ↑ 0.0% |
Net Income | -1.8M | ↑ 0.0% |
Net Profit Margin | -4.2K% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 20.4M | ↓ 58.47% |
Total Liabilities | 3.5M | ↓ 75.8% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 40.5M | ↑ 51.12% |
Total Liabilities | 14.8M | ↑ 222.07% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 13.2M | ↓ 68.22% |
Total Liabilities | 4.2M | ↓ 72.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 17.2M | ↑ 31.54% |
Total Liabilities | 3.3M | ↓ 20.6% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.7M | ↓ 57.21% |
Total Liabilities | 2.9M | ↓ 3.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 13.3M | ↑ 90.81% |
Total Liabilities | 7.4M | ↑ 148.16% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.5M | ↓ 42.94% |
Total Liabilities | 2.4M | ↑ 7.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.7M | ↑ 0.0% |
Total Liabilities | 2.9M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.7M | ↑ 44.11% |
Total Liabilities | 3.2M | ↑ 12.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.1M | ↑ 0.0% |
Total Liabilities | 3.4M | ↓ 0.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.5M | ↑ 32.4% |
Total Liabilities | 5.9M | ↑ 120.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.3M | ↑ 0.0% |
Total Liabilities | 7.4M | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↓ 51.75% |
Investing Cash Flow | -5.0M | - |
Financing Cash Flow | 24.5M | ↓ 389.45% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↑ 43.33% |
Investing Cash Flow | 3.5M | ↓ 167.61% |
Financing Cash Flow | 4.1M | ↓ 83.54% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.0M | ↓ 35.4% |
Investing Cash Flow | -369.9K | ↓ 110.8% |
Financing Cash Flow | 11.7M | ↑ 185.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 0.85% |
Investing Cash Flow | 11.3K | - |
Financing Cash Flow | 70.9K | ↓ 260.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↑ 0.0% |
Investing Cash Flow | 12.2K | ↑ 0.0% |
Financing Cash Flow | 76.1K | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.4M | ↑ 10.6% |
Investing Cash Flow | 12.1K | ↑ 0.0% |
Financing Cash Flow | 3.8M | ↑ 4901.6% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.5M | ↑ 0.0% |
Investing Cash Flow | 12.6K | ↑ 0.0% |
Financing Cash Flow | 3.9M | ↑ 0.0% |
Sell
Neutral
Buy
Biodexa Pharmaceuticals Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biodexa Pharmaceuticals Plc | -38.31% | -72.32% | -94.38% | -99.04% | -99.04% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biodexa Pharmaceuticals Plc | NA | NA | NA | 0.0 | -1.81 | -0.51 | NA | 1.57 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biodexa Pharmaceuticals Plc | Buy | $5.8M | -99.04% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Biodexa Pharmaceuticals Plc
Revenue is down for the last 3 quarters, 149.0K → 41.5K (in $), with an average decrease of 36.1% per quarter
Netprofit is up for the last 5 quarters, -2.29M → -1.75M (in $), with an average increase of 7.6% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 131.5%
midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b
Organization | Biodexa Pharmaceuticals Plc |
Employees | 21 |
CEO | Mr. Stephen A. Stamp |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.36
-8.43%
Keyarch Acquisition Corp
$0.36
-8.43%
Connexa Sports Technologies Inc
$0.36
-8.43%
Us Value Etf
$0.36
-8.43%
First Wave Biopharma Inc
$0.36
-8.43%
Global X Msci Next Emerging
$0.36
-8.43%
Fat Projects Acquisition Corp
$0.36
-8.43%
Capital Link Global Fintech
$0.36
-8.43%
Applied Uv Inc
$0.36
-8.43%